(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

PHARNEXT

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

PHARNEXT

ST13

US500000079316694

Class

5, 35, 42, 44

Filing

79316694

Registration

6749459

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

30

Latest update

10/10/2022

Trademark type

Combined

Nice classes

5, 35, 42, 44

Filing date

03/01/2021

Registration date

06/07/2022

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

06/07/2022

Last transaction

06/10/2022

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

3

Owner type

99

Owner location

FR

Examiner

PEISECKI, MARK A

Law office

L50

Current location

PUBLICATION AND ISSUE SECTION

Mark description

The mark consists of the stylized wording "PHARNEXT", with "PHAR" stacked above "NEXT", all superimposed on a shaded diamond design.

Holders and representatives

Holders

PHARNEXT

Representatives

Pradeep Jayaraman IpHorgan Ltd.

Technical classification

Nice Classes

Class 5Class 35Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Medicinespharmaceutical and veterinary productspharmaceutical preparations for human and veterinary usebiological preparations for medical usediagnostic products for medical usechemical preparations for medical use all for the treatment of neurologicalneurodegenerativeneuromuscular and neuropathic diseasestraumatic neuropathies and demyelinating neuropathiesautoimmune diseasescancerscardiovascular diseasesmetabolic syndromes; food supplements and nutritional supplements for medical use; dietetic food and substances in the nature of beverages adapted for medical and pharmaceutical use; homeopathic and phytotherapeutic preparationshomeopathic plant-based supplements; hygienic products for medicinedisinfectant for hygienic purposes; medicated bath preparations; dietetic beverages for medical use; chemical reagents for medical usebiomarkers; products for personal hygiene for medical purposesdisinfectant for hygienic purposes; medical plastersgauzewaddingbandages for dressings; medical dressings

Class 35

Creationcompilation and management of databases and central data files in the field of pharmaceutical research and developmentmedicinegenetics and clinical trials; compilation of statistics in the field of health and medicine; collection and systemization of data in a central file in the field of pharmaceuticalhealth and medical research and development; public relations in the field of health and medicine

Class 42

Development of pharmaceutical products; pharmaceutical research and development; testing on pharmaceutical products; carrying out clinical trials for pharmaceutical products; scientific research regarding medicine; bio-informaticchemical and biological analysis for scientific research purposes; research in the fields of chemistrycosmetologybiologybacteriologynutrition and biotechnology; biological and bio-informatic research services in the field of chemicalbiological and pharmaceutical products; software design and development in the field of pharmaceuticalhealth and medical research; provision of scientific research information regarding pharmaceutical products and medical and scientific research in the field of pharmaceutical products and clinical trials; scientific research on chemical reagents for medical usenamely biomarkers

Class 44

Medical services; pharmaceutical research services; pharmaceutical adviceinformation and advisory services relating to pharmaceutical products; medical information services; provision of medical information; medical information services on the treatment of diseases

Publications

History of USPTO decisions and trademark events.

30 publications found

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

10/10/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

09/21/2022

FIMP

FINAL DISPOSITION PROCESSED

09/21/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

09/07/2022

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

06/07/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

06/07/2022

FIXD

ELECTRONIC RECORD REVIEW COMPLETE

04/29/2022

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

04/08/2022

ERRR

ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED

04/01/2022

GPNX

NOTIFICATION PROCESSED BY IB

02/28/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/15/2022

PUBO

PUBLISHED FOR OPPOSITION

02/15/2022

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

02/09/2022

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

02/09/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

01/26/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

01/07/2022

DOCK

ASSIGNED TO EXAMINER

12/10/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/10/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/09/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

12/09/2021

RFNT

REFUSAL PROCESSED BY IB

11/23/2021

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

10/22/2021

RFRR

REFUSAL PROCESSED BY MPU

10/22/2021

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

09/30/2021

CNRT

NON-FINAL ACTION WRITTEN

09/29/2021

DOCK

ASSIGNED TO EXAMINER

09/23/2021

MAFR

APPLICATION FILING RECEIPT MAILED

08/10/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

08/06/2021

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

08/05/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

07/29/2021

Continuous trademark protection

Get notified about every new filing that threatens PHARNEXT or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.